Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEVG.L Regulatory News (EVG)

  • There is currently no data for EVG

Form 8 (OPD) Evolution Group PLC

31 Aug 2011 12:00

RNS Number : 3331N
Canaccord Financial Inc.
31 August 2011
 

PUBLIC OPENING POSITION DISCLOSURE BY A PARTY TO AN OFFER

Rules 8.1 and 8.2 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Identity of the party to the offer making the disclosure:

Canaccord Financial Inc.

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient

 

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each party to the offer

Evolution Group PLC

(d) Is the party to the offer making the disclosure the offeror or the offeree?

OFFEROR

(e) Date position held:

August 30, 2011

(f) Has the party previously disclosed, or is it today disclosing, under the Code in respect of any other party to this offer?

No

 

2. POSITIONS OF THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates

 

Class of relevant security:

 

1p ordinary

 

 

Interests

Short positions

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

 

 

 

 

(2) Derivatives (other than options):

 

 

 

 

(3) Options and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

None

 

None

 

 

All interests and all short positions should be disclosed.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

 

(b) Rights to subscribe for new securities

 

Class of relevant security in relation to which subscription right exists:

None

Details, including nature of the rights concerned and relevant percentages:

None

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(c) Irrevocable commitments and letters of intent

 

Details of any irrevocable commitments or letters of intent procured by the party to the offer making the disclosure or any person acting in concert with it (see Note 3 on Rule 2.11 of the Code):

 

None

 

 

3. POSITIONS OF PERSONS ACTING IN CONCERT WITH THE PARTY TO THE OFFER MAKING THE DISCLOSURE

 

Details of any interests, short positions and rights to subscribe of any person acting in concert with the party to the offer making the disclosure

Interests

 

 

Name

Number of Evolution Shares

% of Evolution Issued Share Capital

Charles Stanley & Co Limited on behalf of Discretionary managed private and institutional clients

452,244

0.19%

Canaccord Genuity Limited

630

0.0003%

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3 for each additional class of relevant security.

 

Details of any open derivative or option positions, or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer making the disclosure or any person acting in concert with it:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer making the disclosure, or any person acting in concert with it, and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

None

 

 

(c) Attachments

 

Are any Supplemental Forms attached?

 

Supplemental Form 8 (Open Positions)

No

Supplemental Form 8 (SBL)

No

 

Date of disclosure:

August 30, 2011

Contact name:

 Julia Gray

Telephone number:

(416) 687-5315

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service and must also be emailed to the Takeover Panel at monitoring@disclosure.org.uk. The Panel's Market Surveillance Unit is available for consultation in relation to the Code's dealing disclosure requirements on +44 (0)20 7638 0129.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
FEEUAVRRARAWOAR
Date   Source Headline
25th Apr 20243:46 pmRNSChange of Name
22nd Apr 202410:11 amRNSHolding(s) in Company
11th Apr 20243:04 pmRNSHolding(s) in Company
9th Apr 20247:00 amRNSHolding(s) in Company
8th Apr 20244:03 pmRNSHolding(s) in Company
5th Apr 20243:39 pmRNSDirector/PDMR Shareholding
5th Apr 20242:40 pmRNSHolding(s) in Company
4th Apr 20241:59 pmRNSResult of General Meeting
4th Apr 20247:00 amRNSResult of Retail Offer
19th Mar 20245:03 pmRNSRetail Offer
19th Mar 20245:00 pmRNSAcquisition, Fundraising and Change of Name
27th Feb 20247:00 amRNSSFX-01 positive update in bowel cancer models
19th Feb 202411:22 amRNSPositive update on SFX-01 in vitro GBM studies
9th Feb 202411:01 amRNSNotice of Dispute lodged with Stalicla SA
16th Jan 20243:07 pmRNSSeries B Fund Raise by partner, Stalicla SA
29th Dec 202311:29 amRNSHolding(s) in Company
22nd Dec 20237:00 amRNSDirectorate Changes
13th Nov 20237:00 amRNSUpcoming conferences
31st Oct 20237:00 amRNSHalf-year Report
26th Oct 20237:00 amRNSErasmus Medical Center begins glioblastoma studies
19th Oct 20232:26 pmRNSAuthored Article Publication
5th Sep 20237:00 amRNSDirectorate Changes
15th Aug 20237:00 amRNSFinal Report from Phase 1b PK/PD study
3rd Aug 202312:38 pmRNSRule 17 Disclosure
2nd Aug 20237:00 amRNSReturn of rights to Sulforadex from Juvenescence
21st Jul 202312:02 pmRNSResult of AGM
27th Jun 20237:00 amRNSSFX-01 radiosensitisation effect confirmed in-vivo
20th Jun 20231:59 pmRNSNotice of AGM & Posting of Annual Report
19th Jun 20237:00 amRNSGrant Success for Glioblastoma studies
7th Jun 20237:00 amRNSFinal Results
26th May 202311:00 amRNSNotice of Results
22nd Mar 20237:00 amRNSPreliminary results from Phase 1b study
16th Mar 20232:00 pmRNSPrice Monitoring Extension
16th Mar 202311:05 amRNSSecond Price Monitoring Extn
16th Mar 202311:00 amRNSPrice Monitoring Extension
16th Mar 20237:00 amRNSFurther evidence of radiosensitisation by SFX-01
13th Mar 20237:00 amRNSNo exposure to Silicon Valley Bank
25th Jan 20237:00 amRNSClinical trial update
14th Dec 20225:08 pmRNSGrant of Options - Director/PDMR Shareholding
12th Dec 202211:54 amEQSEvgen Pharma 'cash runway in pretty good shape'
8th Dec 20227:00 amRNSHalf-year Report
2nd Dec 20227:00 amRNSNotice of Half Year Results
30th Nov 20222:06 pmRNSSecond Price Monitoring Extn
30th Nov 20222:00 pmRNSPrice Monitoring Extension
16th Nov 20227:00 amRNSStudy started of new SFX-01 tablet formulation
21st Oct 202211:05 amRNSSecond Price Monitoring Extn
21st Oct 202211:00 amRNSPrice Monitoring Extension
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:00 amRNSClinical trial update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.